Company Description
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence.
The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 3, 2023 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Erez Aminov |
Contact Details
Address: 1200 Brickell Avenue, Suite 1950 #1183 Miami, Florida 33131 United States | |
| Phone | 786 432 9792 |
| Website | mirapharmaceuticals.com |
Stock Details
| Ticker Symbol | MIRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 1904286 |
| CUSIP Number | 60458C104 |
| ISIN Number | US60458C1045 |
| Employer ID | 85-3354547 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chief Executive Officer and Chairman |
| Alan Weichselbaum CPA, M.B.A. | Chief Financial Officer and Treasurer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 8-K | Current Report |
| Dec 22, 2025 | 8-K | Current Report |
| Dec 5, 2025 | 8-K | Current Report |
| Dec 5, 2025 | 424B5 | Filing |